The board of directors of Mabpharm Limited announced that the National Medical Products Administration of China (the "NMPA") has approved the clinical trial application of CMAB015 for the treatment of psoriasis and ankylosing spondylitis. CMAB015 (Secukinumab) is a biosimilar candidate for secukinumab. It is expected that CMAB015 may be approved by the NMPA for marketing in the fourth quarter of 2025. CMAB015 targets interleukin 17A (IL-17A) for treating psoriasis and ankylosing spondylitis. Secukinumab is currently the most effective curer for psoriasis, which offers significant efficacy and guarantees a more stable condition after drug withdrawal compared with the peers. Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that the Group will be
able to obtain approval, develop or ultimately market, CMAB015 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.